Dexmethylphenidate in 2026: Where Things Stand

If you rely on Dexmethylphenidate to manage your ADHD, you've probably spent more time than you'd like searching for it at pharmacies. The stimulant shortage that began in late 2022 has dragged on far longer than anyone expected — and Dexmethylphenidate (brand name Focalin) has been one of the hardest-hit medications.

Here's what you need to know about the Dexmethylphenidate shortage as we move through 2026.

Is Dexmethylphenidate Still in Shortage?

Yes. As of early 2026, Dexmethylphenidate extended-release (XR) capsules remain on the ASHP drug shortage list. Multiple manufacturers — including Par, Sandoz, and others — have reported intermittent supply issues across various strengths.

The immediate-release (IR) tablet formulation has generally been easier to find than the XR capsules, but availability still varies significantly by region, pharmacy, and strength.

The situation has improved somewhat compared to the worst of the shortage in 2023–2024, but patients in many areas still struggle to fill their prescriptions consistently.

Why Is Dexmethylphenidate Still Hard to Find?

The shortage has multiple causes that have compounded over the years:

• DEA production quotas: The DEA controls how much Dexmethylphenidate manufacturers can produce each year. While quotas were increased in late 2025, the production ramp-up takes time to translate into pharmacy shelves.
• Increased demand: ADHD diagnoses have continued to rise, particularly among adults. More patients means more prescriptions competing for the same supply.
• Manufacturing complexity: Controlled substance manufacturing involves layers of regulatory oversight. Supply chain disruptions, raw material shortages, and quality control issues can all cause delays.
• Uneven distribution: Even when supply exists, it doesn't reach all pharmacies equally. Some regions and pharmacy chains experience worse shortages than others.

For a deeper dive into these causes, read our explainer on why Dexmethylphenidate is so hard to find.

How Much Does Dexmethylphenidate Cost in 2026?

Cost varies widely depending on whether you're buying brand-name or generic, and whether you have insurance:

• Generic Dexmethylphenidate IR tablets: $19–$66 for 30 tablets at retail. With a discount card like SingleCare or GoodRx, prices can drop to as low as $19 for 30 tablets.
• Generic Dexmethylphenidate XR capsules: $30–$150 for 30 capsules, depending on strength and pharmacy.
• Brand-name Focalin IR: Approximately $143 for 100 tablets at retail.
• Brand-name Focalin XR: $250–$400+ for 30 capsules without insurance.

If cost is a concern, check our full guide on how to save money on Dexmethylphenidate, including coupons, discount cards, and patient assistance programs.

Are There New Options or Changes in 2026?

A few developments are worth noting:

• DEA quota increases: The DEA officially increased production quotas for stimulant medications in late 2025. This should gradually improve supply, though the full impact may not be felt until mid-2026.
• Additional generic manufacturers: More generic manufacturers have entered or re-entered the Dexmethylphenidate market, which should help diversify supply sources.
• Azstarys: This newer medication combines Serdexmethylphenidate (a prodrug of Dexmethylphenidate) with Dexmethylphenidate. It may be an option for some patients, though it's brand-only and expensive without insurance.
• Telehealth prescribing rules: Federal rules around telehealth prescribing of controlled substances have been evolving. Check with your provider about current requirements for in-person vs. telehealth evaluations.

How to Find Dexmethylphenidate in Stock Right Now

Here are the most effective strategies:

1. Use Medfinder to search for pharmacy availability near you — it's the fastest way to find which pharmacies have your medication.
2. Try independent pharmacies — they often have stock when chain pharmacies don't.
3. Call early in the week — pharmacies typically receive shipments Monday through Wednesday.
4. Ask about different strengths — your doctor may be able to adjust your prescription to a strength that's more available.
5. Request a partial fill — pharmacies can legally give you a partial supply while waiting for more stock.

For more detailed strategies, see our guide on how to find Dexmethylphenidate in stock near you.

When Will the Shortage End?

There's no firm end date. The DEA's quota increases and new generic manufacturers should improve the situation throughout 2026, but experts caution that full resolution of the stimulant shortage will take time. Demand continues to grow, and manufacturing capacity doesn't increase overnight.

The best thing you can do is stay proactive: keep checking availability, maintain an open dialogue with your prescriber, and have a backup plan in case your specific strength or formulation isn't available.

Final Thoughts

The Dexmethylphenidate shortage has been an ongoing challenge for patients across the country. While there are signs of improvement in 2026, many patients still face real barriers to getting their medication filled. Don't hesitate to use every tool available — from Medfinder to patient assistance programs to conversations with your doctor about alternatives.

You're not alone in this, and there are people and resources ready to help.